vs
Side-by-side financial comparison of DiamondRock Hospitality Co (DRH) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
DiamondRock Hospitality Co is the larger business by last-quarter revenue ($258.2M vs $177.4M, roughly 1.5× Pacira BioSciences, Inc.). DiamondRock Hospitality Co runs the higher net margin — 5.6% vs 1.6%, a 4.0% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 1.3%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -8.6%).
DiamondRock Hospitality Co is a US-based real estate investment trust owning and operating a portfolio of premium upscale hotels and resorts. Its properties are mainly located in major urban tourist and business hubs nationwide, catering to both leisure and corporate clientele seeking high-quality accommodation services.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
DRH vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $258.2M | $177.4M |
| Net Profit | $14.5M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 11.1% | 3.9% |
| Net Margin | 5.6% | 1.6% |
| Revenue YoY | 1.3% | 5.0% |
| Net Profit YoY | 22.0% | — |
| EPS (diluted) | $0.07 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $258.2M | $177.4M | ||
| Q4 25 | $274.5M | $196.9M | ||
| Q3 25 | $285.4M | $179.5M | ||
| Q2 25 | $305.7M | $181.1M | ||
| Q1 25 | $254.9M | $168.9M | ||
| Q4 24 | $279.1M | $187.3M | ||
| Q3 24 | $285.1M | $168.6M | ||
| Q2 24 | $309.3M | $178.0M |
| Q1 26 | $14.5M | $2.9M | ||
| Q4 25 | $26.2M | — | ||
| Q3 25 | $22.5M | $5.4M | ||
| Q2 25 | $40.8M | $-4.8M | ||
| Q1 25 | $11.9M | $4.8M | ||
| Q4 24 | $-11.2M | — | ||
| Q3 24 | $26.4M | $-143.5M | ||
| Q2 24 | $24.5M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | 11.1% | 3.9% | ||
| Q4 25 | 8.9% | 1.2% | ||
| Q3 25 | 8.1% | 3.5% | ||
| Q2 25 | 13.7% | 4.7% | ||
| Q1 25 | 4.3% | 1.2% | ||
| Q4 24 | -3.7% | 13.2% | ||
| Q3 24 | 9.5% | -82.8% | ||
| Q2 24 | 8.4% | 15.9% |
| Q1 26 | 5.6% | 1.6% | ||
| Q4 25 | 9.5% | — | ||
| Q3 25 | 7.9% | 3.0% | ||
| Q2 25 | 13.4% | -2.7% | ||
| Q1 25 | 4.7% | 2.8% | ||
| Q4 24 | -4.0% | — | ||
| Q3 24 | 9.3% | -85.1% | ||
| Q2 24 | 7.9% | 10.6% |
| Q1 26 | $0.07 | $0.07 | ||
| Q4 25 | $0.12 | $0.05 | ||
| Q3 25 | $0.10 | $0.12 | ||
| Q2 25 | $0.18 | $-0.11 | ||
| Q1 25 | $0.04 | $0.10 | ||
| Q4 24 | $-0.06 | $0.38 | ||
| Q3 24 | $0.11 | $-3.11 | ||
| Q2 24 | $0.10 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $39.3M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.4B | $653.9M |
| Total Assets | $3.0B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $39.3M | $144.3M | ||
| Q4 25 | $68.1M | $238.4M | ||
| Q3 25 | $145.3M | $246.3M | ||
| Q2 25 | $52.4M | $445.9M | ||
| Q1 25 | $100.6M | $493.6M | ||
| Q4 24 | $81.4M | $484.6M | ||
| Q3 24 | $75.3M | $453.8M | ||
| Q2 24 | $125.2M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $372.2M | ||
| Q3 25 | $1.1B | $376.7M | ||
| Q2 25 | $1.0B | $580.5M | ||
| Q1 25 | $1.1B | $583.4M | ||
| Q4 24 | $1.1B | $585.3M | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.2B | — |
| Q1 26 | $1.4B | $653.9M | ||
| Q4 25 | $1.4B | $693.1M | ||
| Q3 25 | $1.6B | $727.2M | ||
| Q2 25 | $1.6B | $757.8M | ||
| Q1 25 | $1.6B | $798.5M | ||
| Q4 24 | $1.6B | $778.3M | ||
| Q3 24 | $1.6B | $749.6M | ||
| Q2 24 | $1.6B | $879.3M |
| Q1 26 | $3.0B | $1.2B | ||
| Q4 25 | $3.0B | $1.3B | ||
| Q3 25 | $3.1B | $1.3B | ||
| Q2 25 | $3.1B | $1.5B | ||
| Q1 25 | $3.1B | $1.6B | ||
| Q4 24 | $3.2B | $1.6B | ||
| Q3 24 | $3.2B | $1.5B | ||
| Q2 24 | $3.2B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.76× | 0.54× | ||
| Q3 25 | 0.70× | 0.52× | ||
| Q2 25 | 0.65× | 0.77× | ||
| Q1 25 | 0.70× | 0.73× | ||
| Q4 24 | 0.69× | 0.75× | ||
| Q3 24 | 0.67× | — | ||
| Q2 24 | 0.71× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DRH
| Rooms | $164.1M | 64% |
| Food and beverage | $67.2M | 26% |
| Other | $26.9M | 10% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
